Hironori Tanaka

8PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)HaematologyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

|Feb 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka

|Nov 11, 2025
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease.

Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka

Pageof 2

Frequent Collaborators

7 joint publications

Hideko Ohama

7 joint publications

Atsushi Hiraoka

7 joint publications

Toshifumi Tada

7 joint publications

Kazuya Kariyama